| Autor: |
Ruofan Peng, Chenghao Chen, Qian Chen, Yuwen Zhang, Renjin Huang, Yanjun Zhang, Jianhua Li |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Frontiers in Microbiology, Vol 15 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
1664-302X |
| DOI: |
10.3389/fmicb.2024.1457703 |
| Popis: |
Human respiratory syncytial virus (hRSV) not only affects newborns but also older adults, contributing to a substantial worldwide burden of disease. However, only three approved hRSV vaccines remain commercially available to date. The development of a safe, practical and broad-spectrum vaccine suitable for all age groups remains extremely challenging. Using five different approaches—live-attenuated, recombinant-vector, subunit, particle-based, and mRNA—nearly 30 hRSV vaccine candidates are currently conducting clinical trials worldwide; moreover, > 30 vaccines are under preclinical evaluation. This review presents a comprehensive overview of these hRSV vaccines along with prospects for the development of infectious disease vaccines in the post-COVID-19 pandemic era. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
